 |
 |
|
|
RESÚMENES MAYO 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Interrelations between
psychiatric symptoms and drug-induced movement disorder
Guy Chouinard
J Psychiatry Neurosci 2006;31(3):177-80
Randomized,
Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally
Symptomatic for Psychosis
Thomas H. McGlashan,
Robert B. Zipursky, Diana Perkins, Jean Addington, Tandy Miller, Scott W. Woods, Keith A. Hawkins,
Ralph E. Hoffman, Adrian Preda, Irvin Epstein, Donald
Addington, Stacy Lindborg, Quynh Trzaskoma, Mauricio Tohen, and Alan Breier
American
Journal of Psychiatry 163:790-799, May 2006
Early Detection of the First Episode of
Schizophrenia and Suicidal Behavior
Ingrid Melle,
Jan Olav Johannesen, Svein Friis, Ulrik Haahr,
Inge Joa, Tor K. Larsen,
Stein Opjordsmoen, Bjørn R.
Rund, Erik Simonsen, Per Vaglum, and Thomas McGlashan
American
Journal of Psychiatry 163:800-804, May 2006
Prenatal Exposure to Maternal Genital and
Reproductive Infections and Adult Schizophrenia
Vicki Babulas,
Pam Factor-Litvak, Raymond Goetz, Catherine A.
Schaefer, and Alan S. Brown
American
Journal of Psychiatry 163:927-929, May 2006
A National Study of Violent Behavior
in Persons With Schizophrenia
Jeffrey
W. Swanson, Marvin S. Swartz, Richard A. Van Dorn, Eric B. Elbogen,
H. Ryan Wagner, Robert A. Rosenheck, T. Scott Stroup,
Joseph P. McEvoy, Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63:490-499
Understanding
Gender Differences in Schizophrenia: A Review of the Literature
Taylor, Rachel; Langdon, Robyn
Current
Psychiatry Reviews, Volume 2, Number 2, May 2006, pp. 255-265
Incidence of schizophrenia does not
vary with economic status of the country. Evidence from a systematic review
Sukanta Saha,
Joy Welham, David Chant and
John McGrath
Social
Psychiatry and Psychiatric Epidemiology 2006; Volume 41, Number 5: 338 - 340
Priapism
associated with typical and atypical antipsychotic medications
Wang, Chien-Shu;
Kao, Wei-Tsung; Chen, Chian-Dar;
Tung, Yu-Ping; Lung, For-Wey
International
Clinical Psychopharmacology. 21(4):245-248, July 2006
Acute
Confusional States in the General Elderly Population:
An Overview of Delirium Carmen
Andreescu, Benoit H. Mulsant,
LalithKumar Solai, and
James E. Emanuel
Current Psychosis &
Therapeutics Reports 2006, 4:65-73
Delusional
Disorders in the Elderly
Said Jumaa,
and Frank W. Brown
Current Psychosis &
Therapeutics Reports 2006, 4:92-96
Transition
to psychosis: 6-month follow-up of a Chinese high-risk group in
May M.L. Lam, Se-fong
Hung, Eric Y.H. Chen
Australian
and New Zealand Journal of Psychiatry. Volume 40 Page 414 - May 2006
Treatment
with olanzapine, risperidone
or typical antipsychotic drugs in Asian patients with schizophrenia
Chul Lee, Kuang-Hsien Wu, Hussain Habil, Yulia Dyachkova, Phil Lee
Australian
and New Zealand Journal of Psychiatry. Volume 40 Page 437 - May 2006
Why Do Physicians Switch From One Antipsychotic
Agent to Another?: The "Physician Drug
Stereotype"
Journal of Clinical
Psychopharmacology. 26(3):225-231,
June 2006
Olanzapine
Treatment is Associated with Reduced High Molecular
Weight Adiponectin in Serum: A Potential Mechanism
for Olanzapine-induced Insulin Resistance in Patients
with Schizophrenia.
Richards,
Ayanthi A; Hickman, Ingrid J; Wang, Amy Y.-H; Jones,
Amanda L; Newell, Felicity; Mowry, Bryan J;
Whitehead, Jonathan P; Prins, Johannes B; Macdonald,
Graeme A
Journal of Clinical
Psychopharmacology. 26(3):232-237,
June 2006
Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the
Treatment of Negative Symptoms in Outpatients with Schizophrenia
Alvarez, Enrique; Ciudad, Antonio; Olivares, Jose
Manuel; Bousono, Manuel; Gomez,
Juan Carlos
Journal of Clinical
Psychopharmacology. 26(3):238-249,
June 2006
Essential fatty acids and mental illness
International Review of Psychiatry. Volume 18, Number 2 / April 2006: 81 - 84
Bioactive lipids in schizophrenia
Gregor E. Berger, Stefan Smesny, G. Paul Amminger
International Review of Psychiatry. Volume 18, Number 2 / April 2006: 85 - 98
Prevention of oxidative stress-mediated
neuropathology and improved clinical outcome by adjunctive use of a combination
of antioxidants and omega-3 fatty acids in schizophrenia
Sahebarao P. Mahadik,
Anilkumar Pillai, Sadhana Joshi, Adriana Foster
International Review of Psychiatry. Volume 18, Number 2 / April 2006: 119 - 131
Tardive dyskinesia and essential fatty acids
International Review of Psychiatry. Volume 18, Number 2 / April 2006: 133 - 143
Increased extrapyramidal
symptoms in patients with schizophrenia and a comorbid
substance use disorder
S Potvin,
T Pampoulova, A Mancini-Marië, O Lipp, R-H Bouchard and
Journal of Neurology, Neurosurgery, and Psychiatry 2006;77:796-798
Mechanism of Action of Atypical
Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, Jiri; Bubenikova-Valesova,
Vera; Kopecek, Milan; Palenicek, Tomas; Dockery, Colleen; Mohr, Pavel; Hoschl,
Cyril
CNS Drugs. 20(5):389-409, 2006
Drug Firms Vie to Develop More Effective
Antipsychotics
Jim Rosack
Psychiatr News May 19, 2006; Volume 41, Number 10, page 25
Neuroactive
Steroids are Altered in Schizophrenia and Bipolar
Disorder: Relevance to Pathophysiology and
Therapeutics
Christine E Marx, Robert D
Stevens, Lawrence J Shampine, Veska
Uzunova, William T Trost,
Marian I Butterfield, Mark W Massing, Robert M Hamer,
A Leslie Morrow and Jeffrey A Lieberman
Neuropsychopharmacology (2006) 31, 1249-1263
Neurochemical
Effects of Olanzapine in First-Hospitalization Manic
Adolescents: A Proton Magnetic Resonance Spectroscopy Study
Melissa P DelBello, Kim M Cecil, Caleb M Adler, John P Daniels and
Stephen M Strakowski
Neuropsychopharmacology (2006) 31, 1264-1273
Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia
Rainald Schmidt-Kastner,
Jim van Os, Harry W.M. Steinbusch and Christoph Schmitz
Schizophrenia Research. Volume 84, Issues 2-3, June 2006, Pages 253-271
Are females at special risk of obesity
if they become psychotic? The longitudinal
Helinä Hakko, M. Tuomas
Komulainen, Hannu Koponen, Kaisa Saari, Jaana Laitinen,
Marjo-Riitta Järvelin and
Sari Lindeman
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 15-19
Early-onset of symptoms predicts
conversion to non-affective psychosis in ultra-high risk individuals
G.P. Amminger, S. Leicester, A.R. Yung, L.J. Phillips, G.E.
Berger, S.M. Francey, H.P. Yuen and P.D. McGorry
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 67-76
A prospective, multicenter,
randomized, parallel-group, open-label study of aripiprazole
in the management of patients with schizophrenia or schizoaffective disorder in
general psychiatric practice: Broad Effectiveness Trial With
Aripiprazole (BETA)
Rajiv Tandon, Ronald N. Marcus, Elyse G. Stock, Linda C. Riera, Dusan Kostic,
Miranda Pans, Robert D. McQuade, Margaretta
Nyilas, Taro Iwamoto and David T. Crandall
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 77-89
The effects of eicosapentaenoic
acid in tardive dyskinesia:
A randomized, placebo-controlled trial
Robin Emsley, Dana J.H. Niehaus, Liezl Koen, Piet
P. Oosthuizen, H. Jadri
Turner, Paul Carey, Susan Janse van Rensburg, J. Stefan Maritz and Harald
Murck
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 112-120
Risk factors for completed suicide in
schizophrenia and other chronic psychotic disorders: A case–control study
A. McGirr, M. Tousignant, D. Routhier, L. Pouliot, N. Chawky, H.C. Margolese and G. Turecki
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 132-143
Neural dysfunction and violence in
schizophrenia: An fMRI investigation
Veena Kumari,
Ingrid Aasen, Pamela Taylor, Dominic H. ffytche, Mrigen Das, Ian Barkataki, Sangeeta Goswami, Paul O'Connell, Michael Howlett,
Steven C.R. Williams and Tonmoy Sharma
Schizophrenia Research. Volume 84, Issue 1, May 2006, Pages 144-164
Antipsychotic
treatment and extrapyramidal symptoms amongst
schizophrenic inpatients
M. P. Høiberg and B. Nielsen
Nordic Journal of
Psychiatry.
Volume 60, Number 3 / May 2006: 207 - 212
Physical health and schizophrenia. Medical comorbidity
Mitchell, Alex J; Malone, Darren
Current Opinion in Psychiatry. 19(4):432-437, July 2006
Gender Differences in Patients With Schizophrenia in Terms of Sociodemographic
and Clinical Characteristics
Figen Atalay
and Hakan Atalay
German J Psychiatry 2006;9:41-47
Lithium and Clozapine
Rechallenge: A Retrospective Case Analysis
Richard
A. Kanaan,
and Robert W. Kerwin
J Clin Psychiatry 2006;67:756-760
Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine
or Quetiapine: A Frequently Sampled Intravenous
Glucose Tolerance Test and Minimal Model Analysis
David C.
Henderson, Paul M. Copeland, Christina P. Borba, Tara
B. Daley, Dana D. Nguyen, Enrico Cagliero,
A. Eden Evins, Hui Zhang,
Doug L. Hayden, Oliver Freudenreich, Corinne Cather,
David A. Schoenfeld, and Donald C. Goff
J Clin Psychiatry 2006;67:789-797
Risperidone versus Haloperidol, in Combination
with Lorazepam, in the Treatment of Acute Agitation
and Psychosis: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial
VESER, FREDERICK H; VESER, BELYNDA DUNN; MCMULLAN, JASON T;
ZEALBERG, JOSEPH; CURRIER, GLENN W
Journal of Psychiatric Practice. 12(2):103-108, March 2006
Suicide in Schizophrenia: Findings
from a National Clinical Survey
HUNT, ISABELLE M; KAPUR, NAV; WINDFUHR, KIRSTEN; ROBINSON,
JO; BICKLEY, HARRIET; FLYNN, SANDRA; PARSONS, REBECCA; BURNS, JAMES; SHAW,
JENNY; APPLEBY, LOUIS; the National Confidential Inquiry into Suicide and
Homicide by People with Mental Illness
Journal
of Psychiatric Practice. 12(3):139-147, May 2006
A meta-analysis of profile and
time-course of symptom change in acute schizophrenia treated with atypical antipsychotics
Megan Sherwood,
Allen E. Thornton and William G. Honer
The International Journal of Neuropsychopharmacology (2006), 9: 357-366